v3.26.1
Equity (Tables)
6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Schedule of Presents the Outstanding Warrants
3) The following table presents the outstanding warrants, as of June 30, 2026 and their terms:

 

Date of issuance   Number of
outstanding
warrants(**)
    Exercise price
for one
Ordinary
share(**)
    Expiration date
February 16, 2023     204     $ 17,493     November 29, 2027
February 16, 2023     19 (*)   NIS 64,362     November 29, 2027
June 15, 2023     237     $ 12,600     June 12, 2028
January 25, 2024     847     $ 5,250     January 25, 2029
May 14, 2025     2,198     $ 787.5     May 14, 2030
July 28, 2025     15,110     $ 87.36     July 7, 2030
September 30, 2025     45,627     $ 87.36     September 30, 2030
December 4, 2025     24,573     $ 87.36     December 4, 2030
December 30, 2025     11,447     $ 87.36     December 30, 2030
February 12, 2026     11,447     $ 87.36     February 11, 2031
March 10, 2026     11,447     $ 87.36     March 9, 2031
April 27,2026     11,447     $ 87.36     April 26, 2031
June 1, 2026     99,800     $ 87.36     May 31, 2031
June 15, 2026     149,701     $ 87.36     June 14, 2031

 

(*) Classified as a warrants’ liability of $0.

 

(**) Number of outstanding warrants and exercise prices have been adjusted to give retroactive effect to the down round anti-dilution provision included in the terms of such warrants, as affected by new equity investments up to June 30, 2026 (see also note 9B).
Schedule of Share Option Awards Outstanding and the Related Weighted Average Exercise Price

Information on the share option awards outstanding and the related weighted average exercise price as of and for the six months ended June 30, 2026, are presented in the table below:

 

Relating to options:   Number of
potential
Ordinary
Shares
    Exercise
price range*
    Aggregate
Intrinsic
Value
 
Outstanding at beginning of the period     6,718     $ 2.1-$259,440     $ 504,765  
Granted     -       -       -  
Forfeited     -       -       -  
Expired     -       -       -  
Outstanding at end of the period     6,718     $ 2.1-$259,440     $ 13,085  
Exercisable at end of the period     1,981     $ 2.1-$259,440     $ 4,491  

 

* Per 1 Ordinary Share with no par value.
Schedule of Stock-Based Awards Outstanding

The following table summarizes information about stock-based awards outstanding and exercisable at June 30, 2026:

 

    Outstanding     Exercisable  
Exercise price range   Number of
potential
Ordinary
Shares
    Weighted
average
remaining
contractual life
(years)
    Number of
potential
Ordinary
Shares
    Weighted
average
remaining
contractual life
(years)
 
$2.1-$871.5     6,643       4.3       1,906       4.3  
$42,000-$64,470     40       5.7       40       5.7  
$105,000     6       2.0       6       2.0  
$129,660;$194,550;$259,440     29       5.7       29       5.7  
      6,718       4.3       1,981       4.4  
Schedule of Share-Based Compensation Expense

Share-based compensation expense for the periods ended June 30, 2026 and 2025 was as follows (U.S. dollars in thousands):

 

    Six months ended
June 30
 
    2026     2025  
Cost of revenue     -       7  
Research and development     35       235  
Sales and marketing     173       92  
General and administrative     507       179  
Total share-based compensation expenses     715       513  
Schedule of Fair Value of Option Grants

The calculated fair value of options granted in the six months period ended June 30, 2025 was estimated using the Black-Scholes pricing model with the following assumptions (no options were granted in 2026):

 

Risk-free interest rate     4.57 %
Expected option term (in years)     5  
Expected price volatility     120 %
Fair value of an ordinary share   $ 2,360.4  
Dividend yield     0 %